Question

1-5) How is ⅢIn produced? Name three different radiopharmaceuticals that use min and briefly state what type of imaging procedure each is used for. 6-10) Name two different radiopharmaceuticals that each utilize a different iodine isotope in final, to be administered, form. Give the method of production and half-life for each nuclide used. Then briefly describe how each final pharmaceutical is prepared for use as a radiopharmaceutical, any special storage and handling requirements then lastly what imaging procedure each is used for.

Answer 1

how is "in produce ? Name three different radiopharmaceuticals that use " In and briefly state what type of imaging procedure each is used for.

1. Treatment of Cancers and Tumours

• Americium 241 utilized as antineoplastic.
• · Californium 252 utilized as antineoplastic."
• · Cobalt 60 utilized as antineoplastic.
• · Gold1 94 utilized as antineoplasatic.
• · Holmium 66 (26 h) being created for conclusion and treatment of liver tumors.
• · Iodine-125 (60 d) utilized in malignancy brachytherapy (prostate and mind).
• · Iodine 123 utilized as antineoplastic.
• · Iodine 131 utilized as antineoplastic.
• · Rhenium 186 (3.8 d) utilized for help with discomfort in bone disease. Beta producer with powerless gamma for imaging.
• · Iridium 192 (74 d) provided in wire frame for use as an inner radiotherapy hotspot for disease treatment (utilized at that point expelled)

2. Treatment of Thyroid Disease with Iodine 131

• I-131 is remedially utilized for to treat thyroid malignancy, hyperthyroidism (counting Graves' malady, poisonous multinodular goiter, and dangerous self-governingly working thyroid knobs), and Nontoxic multinodular goiter. vita tissues. I-131 has a physical half-existence of 8.1 days. It produces beta particles (normal vitality of 0.192 MeV, greatest vitality of 0.61 MeV
• I-131 to ablate any remaining tissue, as well as to treat residual thyroid cancer or metastatic thyroid cancer.

3. Palliative Treatment of Bone Metastasis

• Various radioisotopes and pharmaceuticals are used to deliver palliative treatment of bone metastases, including samarium-153 (Sm-153), strontium-89 (Sr-89) chloride, and phosphorus-32 (P-32) sodium phosphate.
• Samarium-153 EDTMP (lexidronan): The most normally utilized radioisotope for this treatment in the United States is Sm-153. Sm-153 has a physical half-existence of 1.9 days and radiates beta particles with a normal vitality of 0.23 MeV (most extreme vitality of 0.81 MeV). Sm-153 has a delicate tissue scope of around 0.6mm, keeping radioactive harm to tissue restricted in bone issue.
• Strontium-89 chloride: Sr-89 consolidates itself into the bone also to calcium. Its essential region of limitation is in zones of osteoblastic action. Sr-89 has a physical half-existence of 50.5 days and transmits beta particles with a normal of 0.58 MeV (most extreme vitality of 1.46MeV). Sr-89 has a delicate tissue scope of around 2.4mm, keeping radiation harm limited in the bone tissue.